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ABSTRACT
A meta-analysis of randomised controlled trials evaluated the effectiveness and safety of teicoplanin
compared to ﬁrst- or second-generation cephalosporins for perioperative anti-infective prophylaxis in
orthopaedic and vascular surgery involving prosthetic material. No differences were found between
teicoplanin and cephalosporins with respect to the development of infection at the site of surgery or in
remote areas of the body. In addition, there were no signiﬁcant differences in reported adverse effects or
mortality. These ﬁndings indicate that both regimens are equally effective in preventing post-operative
infections in orthopaedic and vascular surgery involving prosthetic materials.
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Orthopaedic and vascular surgical procedures are
generally considered to be ‘clean’; however,
infection may occur either in the wound or in
deep tissues at the site of surgery. Infection of a
prosthetic joint or vascular graft is one of the
worst scenarios, and may result in mechanical
loosening, sepsis or amputation [1]. The most
common microorganisms responsible for the
development of infection at the site of surgery
are Gram-positive cocci, among which staphylo-
cocci predominate, accounting for 70–90% of
isolated pathogens [2]. The main reason for this
predominance is the ability of these microorgan-
isms to adhere and multiply, by means of slime
production, in polymers [3]. Other Gram-positive
aerobic and anaerobic cocci, as well as Gram-
negative bacteria, may also be involved.
First- or second-generation cephalosporins are
the antibiotics used most commonly for prophy-
laxis during surgery of this type. However,
knowledge of the microbiology of infections in
orthopaedic and ⁄ or vascular surgery has resulted
in the use of antibiotics with antibacterial action
directed mainly against Gram-positive cocci, and
staphylococci in particular. Thus, glycopeptides
have been considered to be a suitable choice,
especially in an era of increasing prevalence of
methicillin-resistant staphylococci.
Several studies have compared the effectiveness
and toxicity of teicoplanin and cephalosporins as
perioperative anti-infective chemoprophylaxis,
but the results have been inconclusive. A review
of randomised controlled trials (RCTs), based on
searches of PubMed (01 ⁄ 1950 to 10 ⁄ 2004), Current
Contents, the Cochrane central register of con-
trolled trials, and references from relevant articles,
including review papers, identiﬁed six studies
conducted with patients undergoing orthopaedic
or vascular surgery which examined the develop-
ment of infection at the site of surgery or in
a remote area of the body, adverse effects attrib-
uted to the study medications, and ⁄ or mortality
[4–9].
The main characteristics of the analysed RCTs
are shown in Table 1. None of the patients in the
studies had any known allergy to the medications
used, or had received antibiotic therapy for any
reason for a speciﬁed period, ranging from 12 h to
Corresponding author and reprint requests: M. E. Falagas, 9
Neapoleos Street, Marousi 151 23, Greece
E-mail: matthew.falagas@tufts.edu
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
2 weeks, before enrolment into each study. As
shown in Table 1, teicoplanin (400 mg) was
administered intravenously at the induction of
anaesthesia in ﬁve studies [5–9]. In one study [4],
a second intraoperative dose was administered if
the duration of the procedure was > 3 h. The
cephalosporins used in the trials included
cephradine [4], cefazoline [5,6], cephamandole
[7,8] and cefuroxime [9]. Each cephalosporin
was administered intravenously at the induction
of anaesthesia, with additional doses given in
some trials, as shown in Table 1. The heterogen-
eity between studies was assessed by chi-square
test, with p < 0.10 denoting statistical signiﬁ-
cance. Publication bias was assessed by the funnel
plot method using Egger’s test. Pooled ORs and
95% CIs for all primary and secondary outcomes
were calculated, using both the Mantel–Haenszel
ﬁxed effects and the DerSimonian–Laird random
effects models. For all analyses, results from the
ﬁxed effects model are presented only when there
was no heterogeneity between studies; otherwise
results from the random effects model are pre-
sented.
The individual studies, as well as the pooled
OR and 95% CI for development of wound
infections, are presented in Fig. 1. There was no
signiﬁcant difference between the two medica-
tions with respect to the development of wound
infections following analysis of the results of six
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Fig. 1. ORs and 95% CIs for infections at the site of
surgery (the vertical line represents the ‘no difference’
point between the compared groups, and the horizontal
lines the 95% CIs). The squares represent ORs from
the different trials; the size of each square denotes the
proportion of information abstracted from each trial. The
diamond represents the pooled OR for all randomised
controlled trials (OR, 1.32; 95% CI, 0.45–3.84).
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RCTs (OR, 1.32; 95% CI, 0.45–3.84) [4–9]. Addi-
tional analyses revealed no signiﬁcant differences
between patients receiving teicoplanin or
cephalosporins with respect to the development
of infections in remote areas of the body (OR, 0.94;
95% CI, 0.73–1.21; analysis of the results of ﬁve
RCTs [4–8]), reported adverse effects (OR, 0.93;
95% CI, 0.59–1.45; analysis of the results of six
RCTs [4–9]), or mortality (OR, 0.78; 95% CI,
0.35–1.75; analysis of the results of four RCTs
[4,5,8,9]).
Teicoplanin has a half-life of 45–70 h [10,11],
and may therefore be administered as a single-
dose regimen. In contrast, ﬁrst and second-gen-
eration cephalosporins require multiple doses.
Furthermore, the antimicrobial spectrum of tei-
coplanin includes methicillin-resistant staphylo-
cocci, which are part of the skin ﬂora of c. 25% of
patients awaiting total joint replacement [12].
These properties support the selection of a glyco-
peptide for perioperative prophylaxis in ortho-
paedic and vascular surgery involving prosthetic
material. Therefore, it is not surprising that both
vancomycin and teicoplanin are used widely for
this purpose in several countries. However, the
ﬁndings outlined above suggest that there is no
superiority of one antibiotic over the other with
respect to the prevention of infection, the devel-
opment of adverse effects and ⁄ or the overall
mortality.
The above analysis has several limitations.
First, only a few studies were available for use
in the meta-analysis. Second, since only one study
presented data on the follow-up period, results
for this parameter were not presented. Third, the
RCTs were conducted during a prolonged time
period (1988–1999), and may conceal signiﬁcant
differences concerning the microbiology of infec-
tions. Finally, although teicoplanin was the pre-
ferred glycopeptide in all studies analysed, the
cephalosporins used in the trials as a second arm
were not identical and the pattern of administra-
tion was different.
In summary, although the use of glycopeptides
as perioperative prophylaxis is becoming more
popular in various hospital settings and patient
populations worldwide, the results of this meta-
analysis on the evaluation of speciﬁc clinical
outcomes do not favour glycopeptides over ﬁrst
or second-generation cephalosporins in orthopae-
dic and vascular operations involving prosthetic
material. However, teicoplanin may be consid-
ered in hospital settings where the development
of infections with multiresistant Gram-positive
microorganisms is likely. The restriction of gly-
copeptide use to these settings is dictated by the
fact that the additional selection pressure result-
ing from extensive consumption of this class of
antibiotics would probably cause even more
problems with respect to the already alarming
increase in rates of antimicrobial resistance.
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